A Transcatheter Closure of Large-Size Patent Ductus Arteriosus with Severe Degree of Pulmonary Hypertension by Different Types of Devices

Document Type : Original Article

Authors

1 Department of Pediatric Cardiology, College of Medicine, Babylon University, Babylon, Iraq

2 Department of Pediatric Cardiology, College of Medicine, Kufa University, Najaf, Iraq

3 Department of Cardiothoracic Surgery, Shaheed Almehrab Cardiac Surgery and Catheterization, Babylon, Iraq

Abstract

Background: Transcatheter closure is the most common treatment for patent ductus arteriosus (PDA); however employing large PDA is difficult because there are few closure devices, and surgical treatment is risky, especially in young infants with low weight and adults with calcified PDA. This study examines transcatheter closure and pulmonary artery (PA) pressure reversibility in large PDA with severe pulmonary hypertension.
Methods: A prospective research examined high PA pressure in 34 patients with big PDA and severe pulmonary hypertension (PHT) who were closed with various occludes. Clinical and transthoracic echocardiographic follow-up at 4 weeks, 3 months, 6 months, and 12 months post-closure measured PA pressure and closure effectiveness.
Results: In total, 34 big PDAs with significant PHT were transcatheter-closed in 723 individuals. Patients were from a few months old to adults and weighed from 4.25 to 61kg, which were tested by using ADO1, MVSD, AVP2, ASDO, and a stent-closed PDAs. After the intervention, the PA systolic, mean, and diastolic pressures were 36.85±11.12mmHg, 29.24±10.09mmHg, and 23.35±8.82 mmHg, respectively. Moreover, after the intervention, the aortic systolic, mean, and diastolic pressures were 112.38±16.97mmHg, 76.00±9.73mmHg, and 61.88±8.73mmHg, respectively. Two instances showed rebound PA pressure 3 months after effective treatments that did not respond to pulmonary vasodilator therapy. The median size of PDA in 10 cases closed by MVSD was 11.59±3.15mm, and the device size was 16.20±3.46mm; moreover, the defect size in 15 cases closed with ADO I device was 9.19±3.46mm, and the median size of occluder was 11.07±4.06mm. In 4 cases, the median size was 5.15±0.65mm, mostly in infants closed by an AVP2 occluder with a device size of 8.50±1.00mm.
Conclusion: Transcatheter closure of large PDA with severe PHT using the off-labeled device is feasible and effective. Meticulous and continuous assessment and evaluation of PHT response for closure is mandatory to confirm longstanding efficacy and safety.

Keywords

References

  1. Kanabar K, Bootla D, Kaur N, Pruthvi CR, Krishnappa D, Santosh K, et al. Outcomes of transcatheter closure of patent ductus arteriosus with the off-label use of large occluders (≥16 mm). Indian Heart J. 2020;72(2):107-12.
  2. Ye Z, Li Z, Yi H, Zhu Y, Sun Y, Li P, et al. Percutaneous device closure of pediatirc patent ductus arteriosus through femoral artery guidance by transthoracic echocardiography without radiation and contrast agents. J Cardiothorac Surg. 2020;15(1):1-6.
  3. Sant’Anna LO, Costa RN, Ribeiro MS, Nascimento WT, Pereira FL, Neves J, et al. Percutaneous occlusion of patent ductus arteriosus with the Amplatzer® vascular plug II device: early experience in three reference centers. Rev Bras de Cardiol Invasiva. 2012;20(2):191-8
  4. Porstmann W, Wierny L, Warnke H. Der Verschluss des Ductus arteriosus persistens ohne Thorakotomie. Thoraxchirurgie und Vaskuläre Chirurgie. 1967; 15(2):199-203.
  5. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation. 2002;106(12 Suppl 1):176–81.
  6. Jacobs JP, Maruszewski B, Kurosawa H, Jacobs ML, Mavroudis C, Lacour-Gayet FG, et al. Congenital heart surgery databases around the world: do we need a global database? Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2010;13(1):3-19.
  7. Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interven. 2008;71(5):665–70.
  8. Yang SW, Zhou YJ, Hu DY, Liu YY, Shi DM, Guo Yh. Feasibility and safety of transcatheter intervention for complex patent ductus arteriosus. Angioology. 2010;61(4):372-6.
  9. Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation. 2002;106(12 Suppl 1):I76–81.
  10. Yan C, Zhao S, Jiang S, Xu Z, Huang L, Zheng H, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007;93(4):514–8.
  11. Khattak KK, Ullah M, Sheikh AM, Kanwal A, Shah SA. Managment of hypertensive PDA. Pak Armed Forces Med J. 2020;70(Suppl-4):S701-05.
  12. Shah JH, Bhalodiya DK, Rawal AP, Nikam TS. Long-term results of transcatheter closure of large patent ductus arteriosus with severe pulmonary arterial hypertension in pediatric patients. Int J Appl Basic Med Res. 2020;10(1):3-7.
  13. Fallahi M, Alaei F, Khalilian MR, Alaei M, Vahidshahi K, Ansari F, et al. Congenital Heart Defects in Hirschsprung's Disease: A Survey in Iranian Population. Iran J Neonatol. 2022;13(1):36-9.
  14. Aurangzeb AS, Khan MA, Bux H, Kumara V, Sathio SN. Effect on Pulmonary Atery Presssres after Transcatheter Occlusion of Patent Ductus Arteriosus with Severe Pulmonary Artery Hypertension. Pak J Med Health Sci. 2023;17(1):591-93.
  15. Nour A, Abdelrazik Y, Huessin S, Kamel H. Safety and efficacy of percutaneous patent ductus arteriosus closure: a multicenter Egyptian experience. Egypt Heart J. 2022;74(1):1-7.
  16. Khorsandi D, Zarepour A, Rezazadeh I, Ghomi M, Ghanbari R, Zarrabi A, et al. Ionic liquid‐based materials for electrochemical biosensing. Clin Transl Discov. 2022;2(3):e127.
  17. Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol. 2008;129(2):163–71.
  18. Nodar SR, Salazar S, Cárdenas C, Yllán VG. Testicular Tumor in Children: A Rare Case Report. Curr Med Res Pract. 2022;9:25-34.
  19. Thanopoulos BD, Tsaousis GS, Djukic M, Al Hakim F, Eleftherakis NG, Simeunovic SD. Transcatheter closure of high pulmonary artery pressure persistent ductus arteriosus with the Amplatzer muscular ventricular septal defect occluder. Heart. 2002;87(3):260–3.
  20. García-Montes JA, Camacho-Castro A, Sandoval-Jones JP. Closure of large patent ductus arteriosus using the Amplatzer Septal Occluder. Cardiol Young. 2015;25(3):491-495.
  21. Yan C, Zhao S, Jiang S, Xu Z, Huang L, Zheng H, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart. 2007;93(4):514–18.
  22. Mukherjee M, Ogunmoroti O, Jani V, Characteristics of Right Ventricular to Pulmonary Arterial Coupling and Association with Functional Status Among Older Aged Adults from the Multi-Ethnic Study of Atherosclerosis. Am J Cardiol. 2023;196:41-51.
  23. Zabal C, García-Montes JA, Buendía-Hernández A, Calderón-Colmenero J, Patiño-Bahena E, Juanico-Enriquez A, Percu-taneous closure of hypertensive ductus Arteriosus. Heart 2010;96(8):625-29.
  24. García-Montes JA, Camacho-Castro A, Sandoval-Jones JP, Buendía-Hernández A, Calderón-Colmenero J, Patiño-Bahena E, et al. Closure of large patent ductus arteriosus using amplatazer septal occlude. Cardiol Young. 2015;25(3):491-95.
  25. El-Kadeem S, El Nemr S, El Amrousy D, Zoair A. Comparison of transcatheter versus surgical closure of perimembranous ventricular septal defect in pediatric patients: A systematic review and meta-analysis. J Saudi Heart Assoc. 2019;31(4):188-197.

 

Iranian Journal of Neonatology
Volume 14, Issue 4
October 2023
Pages 21-27

Files

Share

How to cite

Statistics